Utah Medical Products, Inc. (UTMD) reported a decline in financial performance for the fiscal year ending December 31, 2025, with total revenues of $38.5 million, a decrease of 5.8% from $40.9 million in 2024. The company's net income also fell by 18.7% to $11.3 million, resulting in earnings per share of $3.48, down from $3.96 in the previous year. The decline in revenue was attributed primarily to a significant drop in sales to its former OEM customer, PendoTECH, which fell from $2.7 million in 2024 to just $0.4 million in 2025, as well as a cancellation of orders from its China distributor for blood pressure monitoring kits.
In terms of operational changes, UTMD's gross profit margin decreased to 57.1% from 59.0% in 2024, largely due to increased operating costs and lower sales volumes. The company maintained a strong cash position, ending the year with $85.8 million in cash and investments, despite returning $4 million in dividends and repurchasing $8.4 million worth of its shares. The total stockholder equity increased to $119.3 million, reflecting a commitment to returning value to shareholders while managing operational challenges.
Strategically, UTMD continues to focus on product development and market expansion. The company has emphasized its commitment to enhancing its neonatal product line and expects to introduce new products in 2026, including high-pressure process control transducers for biopharmaceutical manufacturers. Additionally, UTMD aims to regain market share lost due to recent U.S. government trade policies and to resolve ongoing product liability lawsuits related to the Filshie Clip System, which have been a significant concern for the company.
Operationally, UTMD's workforce consisted of 140 full-time employees, with an average tenure of 17 years, indicating a stable and experienced team. The company also reported a decrease in accounts receivable and inventories, reflecting a more efficient management of working capital. Despite the challenges faced in 2025, UTMD's management remains optimistic about the future, projecting that 2026 revenues will stabilize around the same level as 2025, with potential improvements in gross profit margins as the company continues to innovate and respond to market needs.
About UTAH MEDICAL PRODUCTS INC
Utah Medical Products, Inc. designs and manufactures high-quality, safety-focused medical devices primarily for critical care, obstetrics, neonatal intensive care, gynecology, and urology. Its core offerings include fetal monitoring accessories, neonatal catheters, gynecological electrosurgical tools, and contraceptive devices like the Filshie clip. The company serves global markets through direct sales, distributors, and OEM partnerships, emphasizing clinical utility, reliability, and regulatory compliance.
About 10-K Filings
A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.
Key points about the 10-K:
- Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
-
Content: It includes:
- Detailed financial statements audited by an independent accounting firm
- Management's Discussion and Analysis (MD&A) of financial condition and results
- Description of the company's business, properties, and legal proceedings
- Risk factors and market risks
- Executive compensation and corporate governance information
- Importance: Considered the most comprehensive and important document a public company files with the SEC.
- Length: Often exceeds 100 pages due to its extensive and detailed nature.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.